The genetic basis of complications in T2DM has yet to be fully clarified and there is a profound interaction between predisposing genetic make-up and modifiable risk factors.
heavily methylated to prevent retrotransposition. 2 Recent studies have shown that methylation of the LINE-1 elements is associated with an increased risk of worsening carbohydrate metabolism. 3 It has been previously shown that overall DNA methylation of LINE-1 elements could be considered as a risk factor for T2DM and its complications, independent of other established risk factors. 4 Currently, it is not possible to predict accurately who will develop complications of T2DM. Risk assessment tools, such as the Joint
British Societies Coronary Risk Prediction Chart (JBS2), QRISK2 calculator to estimate the patient's 10-year risk of developing cardiovascular disease (CVD) have limitations. 5 Another important limitation of the use of these tools is that they currently do not take account of the genetic, environmental or epigenetic factors that contribute to the risk of CVD.
We studied global DNA methylation using LINE-1 to assess the relevance of this biomarker in identifying individuals at risk of complications in a longitudinal cohort of T2DM. The identification of this epigenetic biomarker could pave way to predict future health problems and/or detect the individuals at most risk with T2DM.
| WHAT WE D ID
A sample of 794 patients in Salford UK, with T2DM was included in this study. Longitudinal clinical information was available for all these patients for 14 years from year 2002 to 2016.
| LINE-1 quantification
Pyrosequencing was used for methylation quantification: QIAGEN PyroMark Q96 MD pyrosequencer was used for quantification of percentage LINE-1 DNA Methylation. Each patient sample was analysed in duplicate. Methylation at four CpG sites was quantified in duplicate and the mean across the four sites estimated. Duplicate runs within each site were highly correlated.
| Statistical analysis
Data analysis was performed using stata 13 (Statacorp, College Station, TX, USA). LINE-1 DNA methylation at each of four CpG sites generated by pyrosequencing was expressed as a percentage, ie, the proportion of methylated residues in the total DNA sample assayed.
Correlation between methylation at all four CpG sites was high (0.83). Therefore, the mean percentage of all four CpG sites was calculated and tested for associations with phenotypic and metabolic variables such as body mass index (BMI), blood pressure, HbA 1C , high sensitivity CRP and lipid profile.
| Linear regression analysis
Multiple linear regression models were used in an attempt to find a relation between mean percentage methylation and metabolic variables by fitting a linear equation to observed data. Phenotypic variables at baseline (from the year 2002)
were used as dependent variables and mean % methylation at four CpG sites was used as the independent variable to calculate regression coefficients (coefficient) and corresponding 95% confidence intervals (CIs). Models were also fitted within each gender separately.
Longitudinal analysis of annually measured phenotypic outcomes over 14-years period (2002-2016) was performed, with mean % methylation gender, baseline age, baseline BMI and for the effects of the drugs, specifically those which were likely to affect the phenotype as independent variables ie, oral and injectable diabetes treatments, statins and anti-hypertensive agents.
| Logistic regression analysis
A logistic regression model was used for the dichotomous outcome variables such as stroke, myocardial infarction, retinopathy, peripheral neuropathy and death. In the logit model, % mean methylation was used as the independent variable.
| WHAT WE FOUND

| Demographic profile
Global LINE-1 DNA methylation was estimated in a total of 794 T2DM patients. Of these 794 patients, 60% (470) were men and 40% (324) were women. Mean ± SD age across gender was 59.20 ± 12.54 years (mean age for men 58.63 ± 12.30 years and women 60.02 ± 12.85 years). There was no gender difference in age. Baseline characteristics of the participants are given in Table 1 .
By the end of 2016, a total 263 (33%) of the patients were dead (of these 163 were men and 100 were women).
| DNA methylation at four CpG sites of LINE-1
The correlation between methylation at baseline in 2002 at all four CpG sites was high (r = 0.8272). Therefore, the mean of all 
| Association of % mean global LINE-1 DNA methylation with age and gender
Linear regression of mean methylation on age after adjustment for BMI showed no significant association between mean % methylation and age: adjusted coefficient: 0.16 (95% CI −0.44-0.11, P = 0.237).
Further analysis showed there was no significant difference in mean LINE-1 DNA methylation between gender: adjusted coefficient:
0.009 (95% CI −0.000-0.020 P = 0.072).
| Cross-sectional analysis at baseline year 2002
Linear regression analysis at baseline showed that LINE-1 meth- There was no significant influence of gender on these associations.
TA 
| Logistic regression analysis of mean % methylation with diabetes complications
The analysis showed no significant associations between mean percentage methylation at baseline and the development of complications, such as myocardial infarction, stroke, peripheral vascular disease, retinopathy and neuropathy.
| SO WHAT DOE S IT ME AN?
In this well-characterised longitudinal T2DM cohort, with some patients followed up for as long as 14 years, we have demonstrated that a higher degree of LINE-1 methylation is predictive of less weight gain over time with consequent lower future BMI in women (Table 1) . Methylation status at baseline may thus influence weight trajectory in women with T2DM. At baseline, there was a significant association between a higher degree of LINE-1 methylation and lower diastolic blood pressure, lower cholesterol/HDL ratio and lower eGFR. A previous study in T2DM individuals described higher DNA methylation levels in patients with albuminuria compared with those without albuminuria. 7 In that study there was a significant increasing trend in global DNA methylation levels in relation to albuminuria categories (normal range of albuminuria/microalbuminuria/macroalbuminuria). It is noteworthy that the overall methylation level was quite high across the four CpG sites studied in the T2DM patients studied here.
Our study also showed that a higher degree of LINE-1 methylation at baseline was associated with a tendency for cholesterol/HDL cholesterol ratio to fall over the period of follow-up.
Lower levels of DNA methylation has been implicated in the development of atherosclerosis and hypertension. 8 The associ- 
| CON CLUS ION
In a 14-year longitudinal cohort of T2DM individuals, we have demonstrated relations between methylation status and BMI change/ specific metabolic markers. A higher degree of DNA methylation was predictive of less weight gain over time and a lower future BMI in women. DNA methylation may provide useful information as to the likelihood of weight gain in this group with potential clinically relevant implications.
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